Genetic Testing for Pancreatic Cancer

(ACCELERATE Trial)

Overseen by Daniel J Renouf, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: British Columbia Cancer Agency

No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.

Research Team

Daniel J Renouf, MD

Principal Investigator

BC Cancer

Eligibility Criteria

This trial is for individuals with pancreatic ductal adenocarcinoma (PDAC) who are receiving standard chemotherapy. They must be willing to provide blood, tissue, and fluid samples for genetic testing and attend clinic visits every 4 weeks.

Inclusion Criteria

Enrolled in the Personalized Oncogenomics (POG) Program at BC Cancer.

Participants must meet all of the following criteria prior to Pre-Baseline registration:

I am set to receive FOLFIRINOX or gemcitabine as my first treatment.

Exclusion Criteria

I have been deemed unfit for chemotherapy.

I am currently on cancer treatment, except for pre-operative therapy.

Positive pregnancy test.

Treatment Details

Interventions

• Tumour DNA and Proteins (Cancer Vaccine)

Trial Overview The study aims to determine if using genetic information and proteins from tumors can predict how PDAC responds to treatment. It involves regular check-ups, questionnaires every 12 weeks, and providing samples during standard chemo treatment.

Participant Groups

Group I: Resectable Cohort Experimental Treatment 2 Interventions

Participants with resectable PDAC. Participants will provide tumour, fluid, and blood samples for genetic testing and other analyses. Tumour samples will be collected from standard resection surgery and optional biopsies. Fluid samples will be collected from a standard laparoscopy procedure. Blood samples will be collected at several timepoints throughout the study. Participants will receive standard chemotherapy (folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based) regimens.

Group II: Locally Advanced Cohort Experimental Treatment 2 Interventions

Participants with locally advanced PDAC. Participants will provide fluid and blood samples for genetic testing and other analyses. Fluid samples will be collected from a standard laparoscopy procedure. Blood samples will be collected at several timepoints throughout the study. Tumour samples may also be collected, if participants agree to optional biopsies. Participants will receive standard chemotherapy (FOLFIRINOX or gemcitabine-based) regimens.

Group III: Borderline Resectable Cohort Experimental Treatment 2 Interventions

Participants with borderline resectable PDAC. Participants will provide tumour, fluid, and blood samples for genetic testing and other analyses. Tumour samples will be collected from standard resection surgery and optional biopsies. Fluid samples will be collected from a standard laparoscopy procedure. Blood samples will be collected at several timepoints throughout the study. Participants will receive standard chemotherapy (FOLFIRINOX or gemcitabine-based) regimens.

Who Is Running the Clinical Trial?

British Columbia Cancer Agency

Lead Sponsor

Trials

181

Recruited

95,900+

Dr. Kim Nguyen Chi

British Columbia Cancer Agency

Chief Executive Officer since 2023

MD

Dr. Kim Nguyen Chi

British Columbia Cancer Agency

Chief Medical Officer since 2023

MD

Terry Fox Research Institute

Collaborator

Trials

11

Recruited

1,600+

BC Cancer Foundation

Collaborator

Trials

20

Recruited

8,600+